Topics:
Radiation Oncology • Palliation
Do you recommend holding tyrosine-kinase inhibitors for extracranial metastases being treated with SBRT?
If a patient has thoracic metastases being managed with EGFR TKI, do you refrain from SBRT treatment, do you hold the TKI, or can you treat the patient with both therapies simultaneously?
Answer from: Radiation Oncologist at Academic Institution
In general, yes I would recommend holding TKIs during SBRT. Anecdotally from both my own experience and others, there is a small risk of severe pneumonitis in patients on concurrent or recent TKI (much of this with osimertinib which has a reasonably high risk of symptomatic pneumonitis on its own) a...
Sign in or Register to read more